Dichloroisoprenaline

Dichloroisoprenaline
Preferred IUPAC name Dichloroisoprenaline
Systematic name 1-(3,4-Dichlorophenyl)-2-[(propan-2-yl)amino]ethan-1-ol
Other names 1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol Dichlorisoproterenol
Identifiers
CAS number	59-61-0 N
PubChem	5806 (1R), 6951395 (1S), 5806 ()
ChemSpider	5601 (1R) Y, 5324297 (1S) Y, 5601 () Y
KEGG	C11772 N
MeSH	Dichloroisoproterenol
ChEBI	CHEBI:144234 N
ChEMBL	CHEMBL30816 Y
Jmol-3D images	Image 1 Image 2
SMILES CC(C)NCC(O)C1=CC(Cl)=C(Cl)C=C1 Clc1ccc(cc1Cl)C(O)CNC(C)C
InChI InChI=1S/C11H15Cl2NO/c1-7(2)14-6-11(15)8-3-4-9(12)10(13)5-8/h3-5,7,11,14-15H,6H2,1-2H3 Y Key: VKMGSWIFEHZQRS-UHFFFAOYSA-N Y InChI=1/C11H15Cl2NO/c1-7(2)14-6-11(15)8-3-4-9(12)10(13)5-8/h3-5,7,11,14-15H,6H2,1-2H3 Key: VKMGSWIFEHZQRS-UHFFFAOYAS
Properties
Molecular formula	C11H15Cl2NO
Molar mass	248.15 g/mol
N (verify) (what is: Y/N?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Dichloroisoprenaline (DCI), also known as dichlorosisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β₁-adrenergic and β₂-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors.

Although DCI was of no clinical value itself, further developments from DCI eventually led to the development of the clinical candidate pronethalol (withdrawn due to carcinogenicity) and subsequently propranolol (the first clinically-successful beta blocker).

Dichloroisoprenaline is a racemic mixture of enantiomers.

The two enantiomers of dichloroisoprenaline